Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 183.80B |
| Revenue (ttm) | 47.05B |
| Net Income (ttm) | 11.37B |
| Shares Out | 1.96B |
| EPS (ttm) | 5.64 |
| PE Ratio | 16.64 |
| Forward PE | 13.55 |
| Dividend | 3.50 (3.73%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 2,441,925 |
| Average Volume | 3,325,817 |
| Open | 93.51 |
| Previous Close | 93.81 |
| Day's Range | 93.49 - 94.22 |
| 52-Week Range | 81.10 - 102.72 |
| Beta | 0.53 |
| RSI | 55.61 |
| Earnings Date | Apr 29, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to a...
If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)
I've added Novo Nordisk and Novartis to boost The Dividend Income Accelerator's healthcare allocation and global diversification, reducing overall risk and volatility. Both companies are attractively ...
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncol...
Incyte and Novartis settle royalties dispute related to Jakafi
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
GSK plc (NYSE: GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa . Under the agreement, GSK will pay up to $2 billion in total cash consideration. This include...
Greece needs urgent cardiovascular disease action plan, says leading health executive
Greek use of interoperable digital tools and secure data platforms such as the EHDS could boost early detection and personalised treatment, while advancing CVD care, a senior Novartis executive tells ...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
Novartis to keep making malaria drugs if orders dry up amid aid cuts
Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters...
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
The president says big news about drug pricing is coming next week.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
China sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief
Vas Narasimhan argues potential US tariffs on pharma industry are not ‘sensible’
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025 , NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephien...
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...
BioNTech says Novartis executive Zapata-Gomez to become CFO
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal
Key deals this week: Gold Fields, Palo Alto, Novartis, LendingClub and more
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Regulus CVR may be worth $3-$4 a share in Novartis deal - analyst
Regulus Therapeutics (RGLS) sale to Novartis offers $7/share upfront & CVR worth $3-$4/share.
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday. The Dow traded down 0.47% to 40,335.51 while the NASDAQ dipped 1.22% to 17,248.37. The S&P 500 ...